Systemic sclerosis & Raynaud's

Longitudinal global transcriptomic profiling of preclinical systemic sclerosis reveals molecular changes associated with disease progression

Rheumatology (Oxford)Published Prospective cohort study

Authors' conclusion

Participants with PreSSc had a distinct gene expression profile indicating that molecular differences at a transcriptomic level are already present in the preclinical stages of SSc. Furthermore, a reduced NK signature in PBCs was related to SSc progression over time.

Study context

Population
Participants with preclinical SSc (PreSSc) and healthy controls; PBC global gene expression at baseline and follow-up (mean 4.2 years)mean follow-up 4.2 years
Participants
33 / 16 / 14 / 19
Exposure
PreSSc vs healthy controls; evolving vs stable PreSSc at follow-up
  • PreSScn = 33
  • Healthy controls (HCs)n = 16reference
  • Evolving PreSScn = 14
  • Stable PreSScn = 19reference
Outcome
Baseline PBC transcriptome, PreSSc vs HCs
Follow-up
Baseline
Methodological detailslongitudinal, RNA sequencing, modular analysis
  • Longitudinal
  • RNA sequencing
  • Modular analysis

Main finding

As reported in the abstract

Differentially expressed genes

2889

Modules significantly decreased in PreSSc (lymphoid lineage, cytotoxic/NK cell, erythropoiesis)

10

Observational data: associations, not effects.

Further findings

Progression at follow-up · follow-up (mean 4.2 years) — Evolving PreSSc
42.4%

Progression at follow-up · follow-up (mean 4.2 years)

Progression not associated with baseline clinical features or baseline PBC transcript modules

Transcript modules at follow-up

Differentially expressed transcripts, change follow-up vs baseline, stable vs evolving PreSSc (336 up, 213 down), EIF2 signalling upregulated
549
Stable PreSSc normalised down-regulated cytotoxic/NK cell and protein synthesis modules; evolving PreSSc kept their down-regulation

Original publication

Longitudinal global transcriptomic profiling of preclinical systemic sclerosis reveals molecular changes associated with disease progression. Rheumatology (Oxford). Published 30 August 2022. doi:10.1093/rheumatology/keac492

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.